BioMarin Pharma (NASDAQ: BMRN) that Health Canada has approved VIMIZIM (elosulfase alfa) for long-term enzyme replacement therapy in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE